Metabolic control of phenylalanine concentrations in body fluids is essential for cognitive development and executive function. The hepatic phenylalanine hydroxylating system is regulated by the ratio of L-phenylalanine, which is substrate of phenylalanine hydroxylase (PAH), to the PAH cofactor tetrahydrobiopterin (BH 4 ). Physiologically, phenylalanine availability is governed by nutrient intake, whereas liver BH 4 is kept at constant level. In phenylketonuria, PAH deficiency leads to elevated blood phenylalanine and is often caused by PAH protein misfolding with loss of function. Here, we report secondary hepatic BH 4 deficiency in Pah-deficient mice. Alterations in de novo synthesis and turnover of BH 4 were ruled out as molecular causes. We demonstrate that kinetically instable and aggregation-prone variant Pah proteins trap BH 4 , shifting the pool of free BH 4 towards bound BH 4 . Interference of PAH protein misfolding with metabolite-based control of L-phenylalanine turnover suggests a mechanistic link between perturbation of protein homeostasis and disturbed regulation of metabolic pathways.
Introduction
The pteridine derivative tetrahydrobiopterin (BH 4 ; 6R-L-erythro-5,6,7,8-tetrahydrobiopterin) is an essential cofactor for hydroxylation of L-phenylalanine (L-Phe) to L-tyrosine by the enzyme phenylalanine hydroxylase (PAH; EC 1.14.16.1). Hepatocytes are the main site of metabolic clearance of circulating L-Phe. In addition, RNA transcripts have been found in the kidney, the pancreas and the brain (1, 2) ; however, the relevance of the phenylalanine hydroxylating system in these tissues remains unclear. Deficiency of the PAH enzyme due to sequence variation in the PAH gene (NCBI Gene ID 5053) causes the biochemical phenotype of hyperphenylalaninemia, i.e. elevated L-Phe concentrations in the blood and body fluids. The resulting disease phenylketonuria (PKU; OMIM 261600) is the most common inherited disorder of amino acid metabolism with a prevalence of 1-5 in 10 000 individuals in the European descendent population (3) (4) (5) (6) . Residual PAH activity in vivo determines the clinical phenotype of PKU patients, ranging from severe classical PKU via mild PKU to mild hyperphenylalaninemia, with increasing activity and decreasing blood L-Phe concentrations (7) (8) (9) .
Binding of BH 4 and L-Phe to PAH is complexly regulated (10) (11) (12) . While the blood L-Phe concentration, even in healthy individuals, is subject to changes of up to 50% within 24 h, depending on nutritional intake and the metabolic state (13) , the concentration of BH 4 is constantly kept at a level of 8-12 mM in hepatocytes (14, 15) . High concentrations of L-Phe lead to substrate-activation of the PAH enzyme, which is induced by allosteric conformational rearrangements (16) (17) (18) (19) (20) . In contrast, binding of BH 4 to non-activated PAH induces a resting t-state (21-23), hence, BH 4 inhibits PAH activity at low L-Phe concentrations. Therefore, binding of BH 4 to PAH depends on the availability of L-Phe and the conformational state of the PAH enzyme. As a consequence, two pools of hepatic BH 4 exist, free BH 4 and BH 4 bound to PAH (15) . Moreover, residual enzyme activity in PKU patients is driven by the interplay of L-Phe and BH 4 concentrations (24) .
Loss of PAH enzymatic function has been shown to result from misfolding, conformational destabilization and rapid degradation, as a consequence of amino acid side-chain replacements in the PAH protein (25) (26) (27) . The discovery of PAH conformational stabilization by BH 4 -binding enabled implementation of a pharmacological treatment for PKU that addresses the lossof-function molecular phenotype (28) (29) (30) . The active compound sapropterin dihydrochloride, a synthetic form of BH 4 , is not efficacious for all PKU patients (28, 31) and drug response depends on the underlying genotype (32) (33) (34) (35) . In the group of patients treated with pharmacological doses of BH 4 , not only L-Phe concentrations but also blood BH 4 concentrations undergo significant changes (36) (37) (38) . Pharmacokinetics of BH 4 following oral administration have been studied in healthy subjects (36) as well as in PKU patients (37-39) and high intra-individual and inter-individual variability of blood BH 4 was observed. Animal studies showed accumulation of BH 4 in liver and kidney after oral or intravenous application (40) (41) (42) . However, the impact of the genotype and of therapeutic BH 4 supplementation on biopterin levels in the liver, where the phenylalanine hydroxylating system is mainly active, is not well understood and pools of liver BH 4 have not been investigated in vivo.
Two PKU mouse models carrying nucleotide substitutions in the murine Pah gene are available (43) . The loss-of-function variant c.835T>C (p.Phe263Ser), which affects the catalytic core of the murine Pah enzyme, leads to a severe classical PKU phenotype in Pah enu2/2 mice. In contrast, the mild hyperphenylalaninemia phenotype observed for Pah enu1/1 is due to the variant c.364T>C (p.Val106Ala), which induces misfolding and degradation of murine Pah (44) . The hybrid Pah enu1/2 was described as a model for compound heterozygous PAH deficiency with a mild PKU phenotype (45, 46 To investigate the liver phenylalanine hydroxylating system independent of blood-derived factors, we isolated hepatocytes and determined Pah activity and BH 4 concentrations ex vivo. Pah activities were compared with concentrations of L-Phe and BH 4 in the blood of donor animals. Genotype-specific hepatic Pah activity observed in isolated hepatocytes (Fig. 1A , Supplemetary Material, Table S1 ) was in line with Pah enzyme activity measured in whole liver lysates (44, 47 , associated with low Pah activity, exhibited L-Phe levels in the range of mild hyperphenylalaninemia. Elevated levels of blood L-Phe induce upregulation of GTP cyclohydrolase 1, the rate-limiting enzyme in BH 4 de novo synthesis (48, 49) . The pattern of blood L-Phe concentrations was comparable to the pattern of blood BH 4 levels determined in different murine PKU genotypes (Fig. 1C, Supplementary Material (50) . This 'uncoupled' reaction leads to a non-stoichiometric consumption of BH 4 , which has been reported for variant human PAH proteins (51) . To assess potential differences in BH 4 consumption and BH 2 production between murine wild-type and p.Val106Ala Pah, we performed activity assays with subsequent analyses of BH 4 and BH 2 concentrations in the assay samples ( Fig. 2B-D , Supplementary Material, Table S2 ). Pah activities determined at standard conditions (1 mM L-Phe; 75 mM BH 4 ) were comparable to data from activity landscapes. Wild-type Pah and p.Val106Ala showed lower BH 4 concentrations in assay samples as compared to the no-protein control. This is in line with BH 4 consumption due to Pah enzyme activity. The oxidation rates of BH 4 to BH 2 correlated with the rates of L-Phe hydroxylation. For the enzymatically inactive variant p.Phe263Ser, the oxidation rate of BH 4 to BH 2 was at the level of the control.
When viewed in combination, these functional studies did not give evidence for a different need for BH 4 
Missense variant-induced misfolding and aggregation of p.Val106Ala controls intracellular BH 4 availability
With the aim to investigate the cause of BH 4 deficiency independent of factors present in isolated hepatocytes, we expressed murine wild-type Pah, p.Val106Ala or p.Phe263Ser in the eukaryotic fibroblast cell line COS-7, which lacks BH 4 de novo synthesis. COS-7 cells convert the precursor sepiapterin to BH 4 via the pterin salvage pathway (52, 53) . When cells were incubated with 40 mM of sepiapterin for 24 h, a variant-specific pattern of intracellular accumulation of free BH 4 was observed ( Significant differences compared to the wild-type (WT) are indicated (***P 0.001, **P < 0.01, *P 0.05, ns P > 0.05) for all experiments. Values are given as means 6 SD.
concentration of sepiapterin, hence the precursor was fully converted to BH 4 . For all cells expressing murine Pah, the BH 4 -concentration was reduced with the lowest concentration observed for p.Val106Ala (30 mM), however these observations did not reach level of statistical significance. After washing off sepiapterin and 4 h incubation without sepiapterin, free BH 4 was overall decreased. The concentration of free BH 4 in cells expressing p.Val106Ala (4 mM) was about 2-fold lower than in cells expressing wild-type Pah (10 mM), which corresponded to the data from isolated hepatocytes ( Therefore, we hypothesized that lower concentrations of BH 4 in isolated hepatocytes or COS-7 cells expressing p.Val106Ala-Pah were due to differences in the ratio of free and bound BH 4 . Replacement of valine by alanine at position 106 leads to misfolding of Pah with reduced proteolytic and thermal stability as well as an increase in hydrophobicity and aggregation kinetics (44, 54 Table S4 ). All BH 4 that was added to the no protein control (CTRL1) was recovered after steps of centrifugation and denaturation and there was no crosscontamination of proteins with exogenous BH 4 (CTRL 2). Given 
Discussion
Tight control of phenylalanine concentrations in body fluids is essential for cognitive development in children and executive function in adults. The phenylalanine hydroxylating system in the liver is rate limiting for disposal of nutrient phenylalanine intake and its function is primarily regulated by the ratio of L-Phe to BH 4 .
Here we demonstrate that secondary BH 4 deficiency contributes to loss of metabolic function in the phenylalanine pathway and dissect a mechanism how variant-induced perturbation of protein homeostasis interferes with metabolic regulation. A balanced metabolism of the essential amino acid L-Phe depends on multifaceted PAH gene-environment and genenutrition interactions. Availability of phenylalanine is mainly governed by nutrient intake. Phenylalanine binding to an N-terminal allosteric site of PAH induces conformational enzyme activation (20, 55) but at low L-Phe concentrations, BH 4 acts as inhibitor of PAH to avoid depletion of phenylalanine from body fluids. In liver cells, BH 4 is generally adjusted to equimolarity with the PAH protein ($10 mM) (14,15) ; however, treatment of a subset of patients with pharmacological doses of BH 4 subjects blood concentrations to changes of 4-to 10-fold over baseline (36, 37, 39) . Given a K M of $24 mM for BH 4 , the PAH enzyme works at suboptimal conditions at physiologic BH 4 concentrations. With increasing phenylalanine concentrations human PAH needs more BH 4 to reach peak activity (24, 56) . Pah activity landscapes showed that, for maximum phenylalanine turnover, the murine Pah hydroxylating system requires BH 4 concentrations far above the physiologic range. The adaptation to a higher need for BH 4 at elevated blood phenylalanine concentrations in Pah deficient mice occurs by an increase in BH 4 de novo synthesis as shown by elevated levels of Gch1 mRNA. A 10-fold increase in blood phenylalanine for . Previous studies described kinetic instability of p.Val106Ala-Pah with proneness to misfolding and aggregation (44, 45) . Here we used an in vitro model where purified p.Val106Ala was partially aggregated but not unfolded while wild-type Pah maintained a native-like conformation, as shown by intrinsic tryptophan fluorescence. Upon complete denaturation, the wild-type protein released the major share of bound BH 4 , whereas BH 4 was trapped by p.Val106Ala. The misfolded variant Pah shifted the ratio of unbound to bound BH 4 and therefore induced a loss of free BH 4 An imbalance in the ratio of L-Phe and BH 4 due to secondary BH 4 deficiency might interfere with the metabolite controlled regulation of the phenylalanine hydroxylating system in humans. In patients with PAH deficiency, trapping of BH 4 by misfolded variant PAH may lead to a decrease in free BH 4 and therefore reduce the pool of BH 4 available for catalytic degradation of L-Phe. Thus, differences in the need for BH 4 in PKU patients may, at least in part, be driven by genotype-specific and protein misfolding-induced alterations of free hepatic BH 4 . Moreover, trapping of BH 4 by misfolded variant PAH may interfere with pools of pharmacologically administered BH 4 . Hence, our observations may help to optimize strategies to identify BH 4 -responsive patients as well as to implement genotypespecific dosing in BH 4 treatment.
We raised the question whether the observed secondary BH 4 deficiency may affect function and dysfunction of related metabolic pathways. BH 4 plays a centrol role in degradation of aromatic amino acids and is an essential cofactor for PAH, tyrosine hydroxylase and tryptophan hydroxylase, enzymes which are key in the metabolism of neurotransmitters. In addition, BH 4 is an essential cofactor for endothelial nitric oxide synthase (eNOS). Enzyme function depends on cofactor availability (59, 60) and decreased BH 4 availability results in eNOS uncoupling with enhanced production of superoxide instead of nitric oxide (61) . Uncoupling was also reported for conditions of increased BH 4 oxidation (62). For patients suffering from severe malaria (63), increased conversion of BH 4 to BH 2 due to increased oxidative stress and insufficient recycling of BH 2 back to BH 4 has been demonstrated.
In the cell, protein unfolding is a frequent event and protein homeostasis is challenged by general physiological perturbations such as oxidative stress or fever. Intricate networks of molecular chaperones and the ubiquitin-proteasome system are responsible for homeostasis of client proteins (64) (65) (66) , moreover, chaperones mediate degradation of metabolites (67) . In case the cytosolic proteostasis network is unable to handle the variantinduced perturbation of the PAH protein folding energy landscape, energetically trapped misfolded states will accumulate and misfolded protein species will be subjected to the degradation pathway. On the other hand, proteostasis of PAH depends on availability of BH 4 (45) . Dysregulation of PAH proteostasis due to a deficiency in the molecular chaperone DNAJC12 was recently reported, interestingly, this defect could partially be corrected by pharmacological doses of BH 4 (68) .
In this study, we dissect a mechanism how variant-induced perturbation of protein homeostasis interferes with metabolic regulation. Expanding the insight into the complex nature of gene-nutrition and gene-drug interactions will contribute to our knowledge of metabolic pathway architecture and of the adaptation of metabolism to health and disease.
Materials and methods

Plasmid construction
The cDNA of murine Pah (EST clone from imaGene) was cloned into the pcDNA3.1/myc-His C vector (life technologies). Substitutions resulting in murine variants p.Val106Ala and p.Phe263Ser were introduced into the pcDNA3.1 plasmid using the PCR-based QuikChange site-directed mutagenesis kit (Stratagene) and authenticity was verified by DNA sequencing. Subsequently, wild-type and mutant cDNAs were subcloned into the prokaryotic expression vector pMAL-c2E (New England Biolabs) and a Gateway-modified pMAL-c2x vector with an additional TEV cleavage site. For eukaryotic expression of wildtype and variant Pah, the pEF-DEST51 vector (life technologies) was used. Murine genes were amplified using primers containing flanking attB sites and the Kozak sequence at the 5 0 terminus. PCR products were subsequently cloned into the pDONR221 vector (life technologies) followed by subcloning to pEF-DEST51 (life technologies).
Animals
Wild /J) mice were purchased from The Jackson Laboratory (Bar Harbor, USA). The compound heterozygous hybrids Pah enu1/2 were crossbred in our animal facility. Animals were housed under controlled temperature conditions and maintained on a cycle of 12-h light/dark period. Between experiments water and food were available ad libitum. Tests were carried out in adult animals at 2-10 months of age. All animal experiments were performed in accordance with German animal protection law.
Measurement of blood phenylalanine levels
Prior determination of blood L-Phe concentrations, mice were kept on normal diet. Blood samples were collected and spotted onto the filter cards immediately after the mice were sacrificed. The analysis was performed via electrospray ionization tandem mass spectrometry in the laboratory of R. Fingerhut (Kinderspital Zurich).
Isolation of murine hepatocytes
The hepatocytes were harvested according to an existing protocol (69) with minor changes. After isoflurane narcosis and cervical dislocation, the mouse was fixed on a heating plate (39 C). The liver was exposed and a perfusion system through the right atrium was established. 
Quantitative real-time PCR
Total RNA was extracted from isolated murine hepatocytes (2 million cells), which were not lysed after isolation. The contaminating DNA was removed with the help of Masterpure RNA Purification Kit (Epicentre Biotechnologies). Reverse transcription was performed using the QuantiTect Reverse Transcription Kit (Qiagen) and the DNA was stored at -20 C until the real-time PCR was performed. Quantitative PCR was performed with cDNA on a Step One Plus real-time PCR system (Applied Biosystems) using Power SYBR Green PCR Master Mix (Applied Biosystems). Gene expression levels of murine Gch1 were normalized to the housekeeping gene murine Gapdh. b2-microglobulin was used as a positive control. Primers designed for mRNA transcripts are summarized in Supplementary Material, Table S5 .
Protein expression and purification
Escherichia coli DH5a cells were transformed with expression plasmids coding for murine wild-type and variant Pah, which were N-terminally fused to maltose-binding protein (MBP). Recombinant proteins were overexpressed for 20 h at 37 C. and purified as previously described in (12, 44) . For TEV cleaved Pah, affinity purified proteins were incubated overnight at 4 C with TEV protease followed by size exclusion chromatography using Ä KTApurifier (GE Healthcare). The concentration of the isolated tetramers was determined spectrophotometrically with A 280 (1 mg/ml) ¼ 1.63 for MBP-Pah and A 280 nm (1 mg/ml) ¼ 1 for Pah. sodium dodecylsulfate-polyacrylamide gel electrophoresis and Coomassie staining verified homogeneity of purified proteins.
Intrinsic tryptophan fluorescence and right angle light scattering
Intrinsic tryptophan fluorescence and right angle light scattering (RALS) measurements were performed using a Cary Eclipse spectrofluorimeter equipped with a temperature-controlled Peltier multicell holder (Varian). MBP-Pah fusion proteins of the wild-type and the variant p.Val106Ala were analyzed. To monitor the folded and unfolded states of Pah, intrinsic tryptophan fluorescence emission spectra were recorded with excitation at 295 nm; folded and unfolded state of PAH were analyzed at 300 and 350 nm (70) . For unfolding kinetics of wild-type and p.Val106Ala, tryptophan fluorescence intensity of 1 mM protein at 300 and 350 nm (slit width 7 nm) was recorded at 25 C. Data are given as the ratio of fluorescence intensity at 350-300 nm representing the ratio of the unfolded state to the folded state. Additionally, for aggregation kinetics of MBB-Pah wild-type and p.Val106Ala RALS was monitored at 37 C for 90 min (excitation and emission wavelength of 500 nm).
Transient expression of murine Pah in COS-7
COS-7 cells were maintained and transient transfection with pEF-DEST51 cDNA was performed as previously described in (44 
PAH enzyme activity assays
PAH enzyme activity in primary hepatocytes was determined as previously described with modifications (26). 20 ml of the cell lysates were preincubated with 1 mM L-Phe and 1 mg/ml catalase for 5 min at 25 C in 15 mM Na HEPES pH 7.3, followed by 1 min incubation with 10 mM ferrous ammonium sulfate. The reaction was initiated by the addition of 75 mM BH 4 stabilized in 2 mM dithiothreitol (DTT, Sigma-Aldrich), carried out for 60 min at 25 C and stopped by acetic acid followed by 10 min incubation at 95 C. In case of PAH activity assay performed with tetrameric wild-type and variant MBP-Pah 20 ml of 0.01 mg/ml protein was used in the reaction mixture and the reaction was carried out for 1 min. All concentrations mentioned refer to the final concentration in a 100 ml reaction mixture. The amount of L-tyrosine production was measured and quantified by HPLC, assayed as duplicates or triplicates.
To analyze BH 4 usage and BH 2 production during the reaction catalyzed by purified murine wild-type and variant MBP-Pah, the standard PAH activity assay was performed with modifications. The reaction was carried out for 1 min and stopped with 8 M urea to assure protein denaturation and prevent biopterin from undue destruction. In total 40 ml of the reaction mixture was then used in the biopterin assay. As a control, the PAH activity assay was performed without Pah protein.
The multi-well PAH activity assay for determination of activity landscapes using varying concentrations of BH 4 (0-500 mM) and L-Phe (0-4000 mM) was performed and bioinformatically analyzed as previously described in (24) . All PAH activity landscapes were assayed in three to five independent experiments and data were combined.
BH 4 trapping assay
To determine the pools of bound and unbound BH 4 a trapping assay was performed using murine wild-type, p.Val106Ala and p.Phe263Ser MBP-Pah as well as TEV-cleaved murine wild-type and p.Phe263Ser. Equimolar amounts of BH 4 and Pah (40 mM) were incubated for 15 min at room temperature. The mixtures were then transferred to Amicon ultra centrifugal filters (Millipore) and centrifuged for 8 min at 3200 rpm (Hettich Rotana 460R 5624), 4 C. The resulting flowthrough was kept for the analysis of BH 4 content (unbound BH 4 ). The proteins from the upper reservoir were washed three times with 1 ml sizeexclusion buffer (200 mM NaCl and 20 mM HEPES, pH 7.0). To analyze the amount of BH 4 released from the protein (recovered BH 4 ), murine Pah proteins were subjected to 5% TCA and after 30 min incubation time mixtures were centrifuged at 20 000g, 10 min at 4 C. Next, 40 ml of the flowthrough samples as well as TCA-treated samples were used in the biopterin assay. As internal assay controls, samples of native Pah (without BH 4 ) and BH 4 (without Pah) were used. The amount of trapped BH 4 was calculated by subtracting unbound and released BH 4 from the whole amount of the BH 4 measured in the assay. Trapping assay was performed as three independent experiments.
Biopterin assay
Total biopterin concentration was analyzed by HPLC according to established methods (14, 71 ). An aliquot of 40 ml of the sample was mixed with 50 ml of an acidic-(1% I 2 /2% KI in 0.1 M HCl) or alkaline-iodine solution (1% I 2 /2% KI in 0.2 M NaOH) and incubated for 1 h in the dark at room temperature. The reaction was stopped by 20 mM (final concentration) of ascorbic acid (for the acidic reaction) or 20 mM ascorbic acid in HCl (alkaline reaction) followed by centrifugation at 10 000g for 20 min. Biopterin was determined by HPLC equipped with a fluorescence detector (E x ¼ 350 and E m ¼ 450 nm). The amount of tetrahydrobiopterin was determined by calculating the difference of biopterin measured in acidic conditions and biopterin measured in alkaline conditions (36) .
Statistical analyses
One-way analysis of variance (ANOVA) with Dunnett's or Bonferroni's post hoc test was applied for multiple comparisons. Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software).
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